Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of RNA-modulating drugs in the United States. The company develops ELX-02, which is in phase II clinical trial for the treatment of nonsense mutation alport syndrome; ZKN013, which is in investigation phase for the treatment of nonsense mutation recessive dystrophic and junctional epidermolysis bullosa; and ZKN013, which is in investigation phase for the treatment of nonsense mutation familial adenomatous polyposis. It also offers platform technologies, including Turbo-ZM and Ribosome Modulating Agents; and Eukaryotic Ribosomal Selective Glycosides for the treatment of rare and ultra-rare premature stop codon diseases. The company is headquartered in Watertown, Massachusetts.
तुलना करने के लिए मीट्रिक्स | ELOX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधELOXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 0.0x | −0.4x | −0.5x | |
PEG अनुपात | 0.00 | 0.00 | 0.00 | |
क़ीमत/बुक | 0.0x | 0.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 1.4x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 422.4% | 47.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 6.2% | 6.7% | अनलॉक करें |